Eton Pharmaceuticals (ETON) Liabilities and Shareholders Equity (2017 - 2025)

Eton Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $92.1 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $92.1 million, up 21.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $382.3 million (up 119.0% YoY), and the FY2025 annual result was $92.1 million, up 21.01% from the prior year.
• Liabilities and Shareholders Equity came in at $92.1 million for Q4 2025 at Eton Pharmaceuticals, down from $104.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $104.5 million in Q3 2025 to a low of $21.5 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $31.1 million (2021), against an average of $44.1 million.
• Across the five-year window, Liabilities and Shareholders Equity fell 25.62% in 2022 and jumped 219.5% in 2025, its largest moves.
• Eton Pharmaceuticals' Liabilities and Shareholders Equity stood at $27.5 million in 2021, then dropped by 8.87% to $25.0 million in 2022, then increased by 26.81% to $31.7 million in 2023, then surged by 139.83% to $76.1 million in 2024, then increased by 21.01% to $92.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $92.1 million (Q4 2025), $104.5 million (Q3 2025), and $101.7 million (Q2 2025), per Business Quant data.